NZ588877A - Methods of using corticotropin-releasing factor for the treatment of cancer - Google Patents

Methods of using corticotropin-releasing factor for the treatment of cancer

Info

Publication number
NZ588877A
NZ588877A NZ588877A NZ58887709A NZ588877A NZ 588877 A NZ588877 A NZ 588877A NZ 588877 A NZ588877 A NZ 588877A NZ 58887709 A NZ58887709 A NZ 58887709A NZ 588877 A NZ588877 A NZ 588877A
Authority
NZ
New Zealand
Prior art keywords
releasing factor
corticotropin
cancer
treatment
methods
Prior art date
Application number
NZ588877A
Other languages
English (en)
Inventor
Stephen Evans-Freke
Original Assignee
Neutron Row
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neutron Row filed Critical Neutron Row
Publication of NZ588877A publication Critical patent/NZ588877A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2228—Corticotropin releasing factor [CRF] (Urotensin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NZ588877A 2008-04-30 2009-04-30 Methods of using corticotropin-releasing factor for the treatment of cancer NZ588877A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4929208P 2008-04-30 2008-04-30
US9480608P 2008-09-05 2008-09-05
PCT/US2009/002645 WO2009134396A2 (en) 2008-04-30 2009-04-30 Methods of using corticotropin-releasing factor for the treatment of cancer

Publications (1)

Publication Number Publication Date
NZ588877A true NZ588877A (en) 2012-08-31

Family

ID=41119761

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ588877A NZ588877A (en) 2008-04-30 2009-04-30 Methods of using corticotropin-releasing factor for the treatment of cancer

Country Status (17)

Country Link
US (1) US20100113341A1 (enExample)
EP (1) EP2259793A2 (enExample)
JP (1) JP2011519375A (enExample)
KR (1) KR20110021820A (enExample)
CN (1) CN102036680A (enExample)
AU (1) AU2009241813A1 (enExample)
CA (1) CA2722426A1 (enExample)
CO (1) CO6300959A2 (enExample)
CR (1) CR11762A (enExample)
EC (1) ECSP10010631A (enExample)
IL (1) IL209005A0 (enExample)
MX (1) MX2010011882A (enExample)
NI (1) NI201000185A (enExample)
NZ (1) NZ588877A (enExample)
RU (1) RU2010148803A (enExample)
WO (1) WO2009134396A2 (enExample)
ZA (1) ZA201007729B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010057962A2 (en) * 2008-11-19 2010-05-27 Neutron Limited Crf conjugates with extended half-lives
KR20120124353A (ko) * 2009-06-24 2012-11-13 스티븐 에반스-프레케 암 치료를 위해 코르티코트로핀 방출인자를 사용하는 방법

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2852054A (en) * 1956-11-23 1958-09-16 Motley Murat Brunson Container and closure therefor
US4312523A (en) * 1979-10-29 1982-01-26 Paco Packaging Incorporated Label for container having pharmaceutical product therein
US4415558A (en) 1981-06-08 1983-11-15 The Salk Institute For Biological Studies CRF And analogs
WO1984001378A1 (en) 1982-09-29 1984-04-12 Karl P Lederis Urotensin peptides
US4528189A (en) * 1983-02-03 1985-07-09 The Salk Institute For Biological Studies Urotensin peptides
US4489163A (en) * 1983-04-14 1984-12-18 The Salk Institute For Biological Studies rCRF and analogs
US5391485A (en) * 1985-08-06 1995-02-21 Immunex Corporation DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues
JPS63500636A (ja) * 1985-08-23 1988-03-10 麒麟麦酒株式会社 多分化能性顆粒球コロニー刺激因子をコードするｄｎａ
US4810643A (en) * 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
US5342940A (en) * 1989-05-27 1994-08-30 Sumitomo Pharmaceuticals Company, Limited Polyethylene glycol derivatives, process for preparing the same
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5229940A (en) * 1992-01-29 1993-07-20 Conoco Inc. Method of extracting three dimensional information from a grid of two dimensional seismic data
US5360352A (en) * 1992-12-24 1994-11-01 The Whitaker Corporation Wire retainer for current mode coupler
US5932462A (en) * 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5780431A (en) * 1996-09-20 1998-07-14 Neurobiological Technologies, Inc. Pharmaceutical formulations of corticotropin releasing factor having improved stability in liquid form
US6319900B1 (en) * 1999-09-21 2001-11-20 The Regents Of The University Of California Inhibition of abnormal cell growth with corticotropin-releasing hormone analogs
CN1361180A (zh) * 2000-12-26 2002-07-31 上海博德基因开发有限公司 一种新的多肽——促肾上腺皮质激素释放因子8.8和编码这种多肽的多核苷酸
CN1382700A (zh) * 2001-04-26 2002-12-04 上海博德基因开发有限公司 一种多肽——促肾上腺皮质激素释放因子－12.87和编码这种多肽的多核苷酸
CA2358177A1 (en) * 2001-10-03 2003-04-03 Ted Ramsay Label for pharmaceutical prescriptions
US7919118B2 (en) * 2003-05-12 2011-04-05 Affymax, Inc. Spacer moiety for poly (ethylene glycol) modified peptide based compounds
WO2005117980A1 (en) * 2004-06-04 2005-12-15 Pfizer Products Inc. Method for treating abnormal cell growth
KR101235723B1 (ko) * 2004-07-08 2013-02-21 아임스코 리미티드 약제
JP2006036013A (ja) * 2004-07-27 2006-02-09 Yamaha Motor Co Ltd 自動二輪車
US7311205B2 (en) * 2005-01-25 2007-12-25 Target Brands, Inc. Pharmacy bottle system including label
US20100203048A1 (en) * 2008-04-30 2010-08-12 Stephen Evans-Freke Methods of using corticotropin-releasing factor for the use of the treatment of cancer

Also Published As

Publication number Publication date
US20100113341A1 (en) 2010-05-06
CA2722426A1 (en) 2009-11-05
AU2009241813A1 (en) 2009-11-05
IL209005A0 (en) 2011-01-31
CR11762A (es) 2011-04-26
RU2010148803A (ru) 2012-06-10
ECSP10010631A (es) 2011-02-28
WO2009134396A2 (en) 2009-11-05
EP2259793A2 (en) 2010-12-15
JP2011519375A (ja) 2011-07-07
NI201000185A (es) 2013-04-22
CO6300959A2 (es) 2011-07-21
WO2009134396A3 (en) 2010-04-15
CN102036680A (zh) 2011-04-27
KR20110021820A (ko) 2011-03-04
MX2010011882A (es) 2011-02-25
ZA201007729B (en) 2014-02-26

Similar Documents

Publication Publication Date Title
MX2011007589A (es) Tratamiento de un cancer usando una combinacion de bendamustine y un anticuerpo anti-cd20.
NZ584458A (en) Tumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells
MX2010010954A (es) Farmaco contra cancer de higado.
MD20150035A2 (ro) Inhibitori de tirozinkinaza Bruton
MX2010004074A (es) Combinacion 059.
NZ700881A (en) Compositions and methods comprising celecoxib or related compounds and dextromethorphan
MX2009013815A (es) Compuestos de quinazolinona y metodos de uso para los mismos.
IL191796A0 (en) Combination of zd6474 and pemetrexed
MX2010009623A (es) Derivados de 1-bencil-3-hidroximetilindazol novedosos y su uso en el tratamiento de enfermedades basadas en la expresion de mcp-1, cx3cr1 y p40.
NZ590464A (en) Antineoplastic combinations of the 4-anilino-3-cyanoquinoline neratinib and capecitabine
MX2011006006A (es) Compuestos, composicion farmaceutica y metodos para utilizarse en el tratamiento de trastornos metabolicos.
WO2010148390A3 (en) Polyamine transport inhibitors as novel therapeutics
MX2010009625A (es) Derivados de 1-bencil-3-hidroximetilindazol y uso de los mismos en el tratamiento de enfermedades basadas en la expresion de mcp-1, cx3cr1 y p40.
WO2009114703A3 (en) Combination therapy for the treatment of cancer
MX2007003505A (es) Combinacion que comprende zd6474 e imatinib.
WO2010033884A3 (en) Method for the treatment of radiation-induced neutropenia by administration of a multi-pegylated granulocyte colony stimulating factor (g-csf) variant
MX2007003506A (es) Terapia de combinacion de cancer que comprende azd2171 e imatinib.
IL191797A0 (en) Combination of azd2171 and pemetrexed
MX2007004955A (es) Metodo de tratar cancer con formulaciones de compeusto de platino a base de lipido administradas intraperitonealmente.
WO2007130501A3 (en) Combination therapy for treatment of cancer
MX2011008994A (es) Metodos de usar sns - 595 para el tratamiento de sujetos con cancer con actividad reducida de brca2.
NZ587941A (en) Methods to inhibit tumor cell growth by using lansoprazole
SG179069A1 (en) Cancer stem cell-targeted and drug resistant cancer therapy
NZ588877A (en) Methods of using corticotropin-releasing factor for the treatment of cancer
WO2011091154A3 (en) Use of human erythrocytes for prevention and treatment of cancer dissemination and growth

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 30 APR 2016 BY CPA GLOBAL

Effective date: 20130412

LAPS Patent lapsed